Photo-Oculodynia is a condition in which eye pain or discomfort is caused by light from sources that would not normally cause pain or discomfort. In 1995, Fine PG and Digre KB distinguished and defined photophobia and photo-oculodynia.
Conceptual distinction from photophobia is as follows:
Photophobia: Discomfort and avoidance behavior in response to light.
Photoaversion: Behavior of avoiding light due to discomfort.
Photo-oculodynia: A condition in which light itself induces pain.
Photophobia and photo-oculodynia often co-occur but are conceptually distinct. They are frequently triggered by ocular trauma and are classified as a rare disease under idiopathic chronic ocular pain syndrome. No established diagnostic criteria or large-scale epidemiological data exist.
Importantly, even totally blind patients can perceive light-induced pain. Vision (image formation) is not necessary for pain generation; non-visual photosensitive pathways are involved in pain signal transmission.
QWhat is the difference between photophobia and photodynia?
A
Photophobia refers to discomfort and avoidance behavior in response to light, whereas photodynia refers to a condition in which light itself causes pain. However, the two often occur together. For details, see also the section on “Pathophysiology and Detailed Mechanisms”.
Physical examination findings are usually unremarkable. The characteristic feature of this disease is that there are no specific positive or negative findings. Diagnosis relies heavily on history taking and validated assessment tools.
The following diseases should be considered in the differential diagnosis.
Keratitis and intermediate opacities (early cataract): Common differential diagnoses for photophobia.
Retinal degenerative diseases such as retinitis pigmentosa: Photophobia is the main complaint.
A history of ocular trauma is considered the greatest risk factor. Related conditions such as anxiety disorders, depression, blepharospasm, or use of certain medications like benzodiazepines may also pose a risk.
Diagnosis is based on patient history, neurological examination, and neuro-ophthalmological examination. No specific diagnostic criteria have been established.
Physical examination findings are usually normal, and diagnosis relies heavily on history and assessment tools. When routine tests are normal for sudden-onset photophobia of unknown cause, electroretinography (ERG) recording is important.
Validated assessment tools include the following:
Bossini et al.’s 16-item photophobia questionnaire: A self-assessment tool validated in an Italian population.
Choi et al.’s photophobia survey for migraine patients: Validated in migraine patients.
FL-41 lenses: Special lenses that block wavelengths around 480 nm, where intrinsically photosensitive retinal ganglion cells (ipRGCs) show maximum response.
Tinted glasses: Important for symptomatic treatment of photophobia.
Smart light bulbs: Allow individual adjustment of light intensity and color (wavelength). In cases of severe idiopathic photophobia, it has been reported that 100% intensity of red and green light was tolerated2).
Botulinum neurotoxin: selective treatment for blepharospasm. It also has some effect on migraine. Botulinum treatment for blepharospasm is considered first-line therapy.
SSRI/SNRI (reference): Examples of prescriptions for pain disorder include starting with one 25 mg tablet of Depromel once daily, increasing to two tablets twice daily after 2–3 weeks (maximum 4 tablets/day), and Lyrica capsules 25 mg three times daily (maximum 150 mg/day).
Clonazepam (reference): An example of a prescription for a patient with near-blindness and severe photophobia is Rivotril tablets 0.5 mg, 1–3 tablets per day divided into 1–3 doses. However, this is not covered by insurance and long-term use should be avoided.
Superior cervical sympathetic ganglion block: May be useful for treating sympathetic-dependent pain syndrome.
Sympatholysis: Although promising results have been obtained in controlled trials, surgery is not the first-line treatment.
QWhat is an FL-41 lens?
A
An FL-41 lens is a special lens that blocks light near the 480 nm wavelength, where ipRGCs (intrinsically photosensitive retinal ganglion cells) show maximum response. It can be used complementarily with light environment adjustment using smart bulbs2).
6. Pathophysiology and detailed mechanism of onset
Eye pain is primarily mediated by the first branch of the trigeminal nerve (V1). Nociceptive afferents travel along cranial nerves III, IV, and VI.
Trigeminal vascular reflex: Noxious stimuli release CGRP and nitric oxide, causing intracranial vasodilation. Via a polysynaptic reflex, the pathway proceeds from the superior salivatory nucleus → pterygopalatine ganglion → parasympathetic nerves → vasodilation.
Trigeminal autonomic reflex: Mechanism of conjunctival injection, lacrimation, and periorbital pain in migraine and cluster headache with photophobia. Via trigeminal spinal nucleus caudalis → superior salivatory nucleus and Edinger-Westphal nucleus.
Sympathetic efferent fibers are densely distributed in the orbit, and stimulation of the superior cervical ganglion causes pain. The involvement of the sympathetic nervous system is suggested by the fact that pharmacological blockade of sympathetic nerves is effective for intractable facial pain that was unresponsive to trigeminal neurectomy.
Suprachiasmatic nucleus pathway: Contributes to circadian rhythm function.
ipRGCs (intrinsically photosensitive retinal ganglion cells): Contain melanopsin instead of rhodopsin. They project light signals to the pretectal olivary nucleus and suprachiasmatic nucleus. They exist not only in the retina but also in the iris.
Trigeminal spinal nucleus caudalis neurons: Their firing rate increases upon light exposure, and signals are transmitted via the parabrachial nucleus → thalamic nuclei → subcortical and cortical areas.
Photophobia neurons: Discharge disappears only with lidocaine injection into both the intraocular afferent pathway and the trigeminal neuron site. These neurons are hypothesized to be “photophobia neurons.”
Parasympathetic contribution: Pain is alleviated by the combination of lidocaine to the superior salivatory nucleus and ocular vasoconstrictors.
Circuit 2
ipRGC neurons: Respond to nociceptive light stimuli via direct connections to thalamic nuclei (posterior nucleus, posterolateral nucleus, intergeniculate leaflet).
Signal transmission: It can be traced to the visual cortex and subcortical areas.
Third Circuit (Proposed)
Thalamocortical interaction: Deep processing relationships between structures may contribute to photophobia.
Research stage: Detailed elucidation of this circuit is expected to clarify its role in photophobia.
CGRP receptors are involved in intracranial nociception in migraine. CGRP receptor antagonists relieve acute migraine, and mice with gain-of-function mutations in the CGRP signaling pathway exhibit migraine-like symptoms.
QWhy do completely blind people still feel pain from light?
A
Image formation (vision) is not essential for pain generation. Non-visual photosensitive pathways such as ipRGCs are involved in transmitting pain signals to the trigeminal nerve and thalamic nuclei, so light-induced pain can occur even in completely blind patients.
7. Latest Research and Future Prospects (Research-stage Reports)
As a cause of sudden-onset photophobia, reports of acquired diffuse occult inner retinopathy (ADOIR) are increasing.
Igawa et al. (2025) reported cases of ADOIR. Characteristic findings include a negative electroretinogram indicating bipolar cell dysfunction, relatively preserved visual acuity, no complaints of night blindness, and normal fundus findings and OCT. Among 17 previously reported cases, 14 were unilateral and 3 were bilateral, with some cases progressing from unilateral to bilateral involvement. In sudden-onset photophobia of unknown cause, electroretinography is important for diagnosis 1).
Light Environment Management Using Smart Light Bulbs
Attempts to use smart light bulbs that can individually adjust light intensity and color (wavelength) for photophobia management have been reported.
Zhou et al. (2021) reported a case of a 18-year-old female with severe idiopathic photophobia using Philips Hue White and Color Ambiance bulbs 2). Red and green light at 100% intensity were tolerated, but blue and white light induced symptoms even at low intensity. It was suggested that they can be used complementarily with FL-41 lenses.
Future research proposes the design of a randomized controlled trial comparing smart light bulbs with a placebo (standard incandescent light). The use of the UPSIS-17 (Utah Photophobia Symptom Impact Scale) has been suggested as an evaluation metric 2).
The prognosis for treatment of photophobia is not fully understood, and further research is expected.
